Vigil Neuroscience’s (VIGL) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $22.00 price target on the stock.

VIGL has been the subject of several other reports. HC Wainwright reissued a buy rating and set a $24.00 target price on shares of Vigil Neuroscience in a research note on Wednesday. JMP Securities reissued a market outperform rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, April 18th.

Vigil Neuroscience Stock Performance

NASDAQ VIGL opened at $3.78 on Wednesday. The firm has a market cap of $142.07 million, a price-to-earnings ratio of -1.77 and a beta of 1.87. The firm has a 50 day simple moving average of $3.08 and a 200-day simple moving average of $3.72. Vigil Neuroscience has a one year low of $2.50 and a one year high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.01). Equities analysts predict that Vigil Neuroscience will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

An institutional investor recently raised its position in Vigil Neuroscience stock. PEAK6 Investments LLC raised its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 66.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,796 shares of the company’s stock after acquiring an additional 9,459 shares during the quarter. PEAK6 Investments LLC owned approximately 0.07% of Vigil Neuroscience worth $128,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.